Building Agent Studio: How Medable Is Using Agentic AI to Accelerate Clinical Trials

Key Takeaways

• No-code platform accelerates AI agent deployment
• ETMF agent classifies 80k+ documents annually
• CRA agent monitors safety across 13 clinical systems
• Custom MCPs ensure secure, authenticated data access
• Evaluation framework meets GXP regulatory standards

Summary

Medable has launched Agent Studio, a no-code/low-code platform that lets pharmaceutical companies configure and deploy AI agents across the clinical trial lifecycle. The platform currently powers two agents—a document‑classification ETMF agent that processes over 80,000 records a year, and a CRA agent that monitors patient safety and data quality across 13 disparate clinical systems. Agent Studio handles retrieval‑augmented generation, custom MCP connectors with authentication, and a regulated GXP‑compliant evaluation framework. By abstracting the underlying AI infrastructure, Medable aims to shave years off the drug‑to‑market timeline.

Pulse Analysis

The pharmaceutical industry faces mounting pressure to reduce the decade‑long timeline for bringing new drugs to market. AI promises to streamline repetitive, data‑intensive tasks, but regulatory constraints and fragmented clinical systems have limited adoption. Medable’s Agent Studio tackles this gap by offering a low‑code environment where AI agents can be built, tested, and deployed without deep engineering effort, enabling sponsors to focus on trial design rather than infrastructure.

At the heart of Agent Studio is a sophisticated architecture that blends retrieval‑augmented generation (RAG) with a unified ontology layer mapping terminology across 13 clinical data sources. Custom Model‑Connector‑Pipelines (MCPs) provide secure, credentialed access to each system, while context‑window management and sub‑agents keep prompt sizes within model limits. The platform’s evaluation pipeline—featuring golden datasets, production monitoring, and human‑in‑the‑loop feedback—meets GXP compliance, ensuring that AI‑driven decisions satisfy regulatory auditors.

From a business perspective, the ability to rapidly spin up agents like the ETMF document classifier and the CRA safety monitor translates into measurable efficiency gains: faster data ingestion, reduced manual review, and earlier detection of safety signals. As Medable expands self‑serve and custom‑build deployment models, the broader market can expect a shift toward more autonomous, AI‑enhanced clinical trials, potentially redefining the economics of drug development. The move positions Medable as a pivotal enabler of the industry’s “full self‑driving” trial vision.